StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX – Free Report) in a research note published on Friday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.
Eagle Pharmaceuticals Stock Down 27.8 %
EGRX opened at $0.65 on Friday. Eagle Pharmaceuticals has a twelve month low of $0.45 and a twelve month high of $14.78. The stock has a market capitalization of $8.44 million, a price-to-earnings ratio of 0.55 and a beta of 0.51. The firm has a 50 day moving average price of $4.10 and a 200-day moving average price of $4.49.
Hedge Funds Weigh In On Eagle Pharmaceuticals
Institutional investors have recently bought and sold shares of the stock. Headlands Technologies LLC raised its stake in shares of Eagle Pharmaceuticals by 75.7% in the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock worth $35,000 after buying an additional 2,861 shares during the period. Mackenzie Financial Corp purchased a new position in Eagle Pharmaceuticals during the second quarter valued at approximately $60,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Eagle Pharmaceuticals in the second quarter worth approximately $65,000. Fidelis Capital Partners LLC purchased a new stake in shares of Eagle Pharmaceuticals in the second quarter worth $71,000. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter valued at $76,000. 85.36% of the stock is owned by institutional investors.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.
Featured Articles
- Five stocks we like better than Eagle Pharmaceuticals
- The How and Why of Investing in Gold Stocks
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- Health Care Stocks Explained: Why You Might Want to Invest
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- NYSE Stocks Give Investors a Variety of Quality Options
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
